Indocyanine Green (ICG) in the ex Vivo Detection of Sentinel Lymph Node (SLN)in Colon Cancer (2068)
Prospective Open-label Study Using ex Vivo Injection of ICG to Detect SLN in Patients With Colon Cancer
調査の概要
状態
状態
詳細な説明
Primary objective Feasibility study of ex vivo injections of ICG to image and detect the sentinel lymph nodes in patients with colon cancer.
Secondary objectives:
To determine the sensitivity of ICG in the dissected piece of colon cancer compared with the blue dye.
Tertiary objectives:
Evaluation of the influence of this approach on the up-staging of the patients
Microscopic study of the ICG distribution in the lymph nodes (in the lymphatic sinuses, in specific cells, in cancerous foci…)
Methodology:
In the operating room:
Patients will undergo standard surgical resection. Immediately after removal of the colon and node-bearing mesentery, using different 29 Gauge insulin syringes, blue dye (2 ml blue dye: 0.5 ml per injection) and ICG (2 ml with 0,5 mg ICG per ml: 0.5 ml per injection) will be injected in the fresh specimen beside each other submucosally around the tumour in at least four sites (as many injections needed to cover all the perimeter of the tumour) for each agent. The injection sites will be then gently stretched and massaged for 3-5 min to stimulate the tracers to flow along the lymphatic channels. Fluoroscopic imagings of the mesentery will be performed during the injections and during these manoeuvers.
The research and identification of the sentinel lymph nodes will be then performed as follows:
- he will first localize the blue colored lymph vessels (if visible) as well as the palpable and/or blue colored lymph nodes. These last ones will be marked for dissection with a blue suture.
- using the PDE camera, he will thereafter localize the fluorescent lymph vessels (if visible) as well as the palpable and/or fluorescent lymph nodes. These last ones will be marked for dissection with a green suture.
Histopathology in the Laboratory of Pathology:
When all SLN are identified, they will be dissected and classified as follows:
- SLN first seen as blue and confirmed also as fluorescent using PDE
- SLN seen as blue but not confirmed to be fluorescent using PDE
- SLN not directly visible as blue but seen fluorescent using PDE (the LN in this group will be controlled for their blue or not character when dissected)
- LN identified by the pathologist as pathological but not blue and not fluorescent.
After the dissection of these SLN, the specimen will be processed as usual using routine procedure for further examination of the non SLN by the pathologists. Once these lymph nodes are dissected, they will be tested for the emitted fluorescence.
研究の種類
研究の種類
入学 (実際)
入学
連絡先と場所
研究場所
-
-
-
Brussels、ベルギー、1000
- Jules Bordet Institute
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
サンプリング方法
調査対象母集団
説明
Inclusion Criteria:
- Patients with histo-pathological diagnosis of colon cancer who are candidate for laparoscopic colectomy,
- Informed consent form signed.
Exclusion Criteria:
- Definite lymph node metastases diagnosed either pre-operatively, or per-operatively
- Inability to give informed consent,
- Age < 18 years old,
- Pregnancy.
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 観測モデル:コホート
- 時間の展望:見込みのある
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
時間枠 |
|---|---|
|
number of sentinel lymph nodes identified in pieces of colectomy from patients with colon cancer with Indocyanine Green
時間枠:18 monthes
|
18 monthes
|
協力者と研究者
捜査官
捜査官
- 主任研究者:Gabriel Liberale, MD、Surgeon in Jules Bordet Institute
研究記録日
主要日程の研究
研究開始
研究開始
一次修了 (実際)
一次修了
研究の完了 (実際)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (見積もり)
最初の投稿
学習記録の更新
投稿された最後の更新 (見積もり)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。